Aardvark Therapeutics Inc

AARDNASDAQ · USD
1.16USD-0.10 (-8.34%)
222

Aardvark Therapeutics Inc (AARD) Covered Calls

Read more

Running AARD covered calls helps you generate income from Aardvark Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best AARD covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If AARD stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling AARD covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given AARD covered call is worth writing.

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation.

2027-05-211897.50463.910.050.20622.00467.67903.17-3.76+0.226210.15

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank—
  • Market cap (M$)28
  • 52 weeks high-92.41%
  • 52 weeks low35.48%
  • Analyst recommendationHold
    2.55
  • Target price$4.00
    295.67% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-13
  • P/E—
  • Future P/E—
  • EPS (ttm)-3.33
  • EPS growth next 5 years8.57%

As of Nov 16, 2026